173 related articles for article (PubMed ID: 28203168)
1. A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy.
Hashida H; Satake H; Kaihara S
Case Rep Oncol; 2017; 10(1):81-85. PubMed ID: 28203168
[TBL] [Abstract][Full Text] [Related]
2. A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated with XELIRI + Bevacizumab Therapy.
Aisu N; Yoshida Y; Ishii F; Miyake T; Tanimura S; Wada Y; Yamauchi Y; Hoshino S; Noritomi T; Yamashita Y
Case Rep Oncol; 2013 Jan; 6(1):143-7. PubMed ID: 23569449
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
5. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
García Alfonso P; Muñoz Martin A; Alvarez Suarez S; Blanco Codeidido M; Mondejar Solis R; Tapia Rico G; López Martín P; Martin M
Onkologie; 2013; 36(6):363-7. PubMed ID: 23774151
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Kocakova I; Melichar B; Kocak I; Bortlicek Z; Büchler T; Dusek L; Petruzelka L; Kohoutek M; Prausová J; Finek J; Mohelnikova-Duchonova B; Vyzula R
Anticancer Res; 2015 Jun; 35(6):3455-61. PubMed ID: 26026110
[TBL] [Abstract][Full Text] [Related]
8. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
9. [Recurrent rectal cancer with multiple liver and lung metastases treated effectively with oxaliplatin and capecitabine plus bevacizumab chemotherapy-a case report].
Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Hasegawa H; Kitagawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1834-6. PubMed ID: 24393938
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Mizushima T; Fukunaga M; Sueda T; Ikeda M; Kato T; Kim HM; Kudo T; Murata K; Nishimura J; Hata T; Matsuda C; Yamamoto H; Doki Y; Mori M
Cancer Chemother Pharmacol; 2017 Jul; 80(1):81-90. PubMed ID: 28510802
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
14. Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature.
Shimazaki J; Motohashi G; Nishida K; Tabuchi T; Ubukata H; Tabuchi T
Oncol Lett; 2014 May; 7(5):1455-1458. PubMed ID: 24765155
[TBL] [Abstract][Full Text] [Related]
15. [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Kocáková I; Kocák I; Svoboda M; Nemecek R; Rehák Z; Standara M
Klin Onkol; 2009; 22(2):73-6. PubMed ID: 19522377
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Ocvirk J; Rebersek M; Boc M
Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
[TBL] [Abstract][Full Text] [Related]
17. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Kuramochi H; Ando M; Itabashi M; Nakajima G; Kawakami K; Hamano M; Hirai E; Yokomizo H; Okuyama R; Araida T; Yoshimatsu K; Kameoka S; Hayashi K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):579-585. PubMed ID: 28213683
[TBL] [Abstract][Full Text] [Related]
19. [Long-Term Survival of a Patient with Advanced Recurrent Rectal Cancer Treated with a Multidisciplinary Therapy including Five Operations-A Case Report].
Nara A; Udagawa M; Onishi I; Sueyoshi K; Gokita K; Watanabe Y; Adikrisna R
Gan To Kagaku Ryoho; 2020 Jan; 47(1):114-116. PubMed ID: 32381876
[TBL] [Abstract][Full Text] [Related]
20. [XELIRI plus Bmab Therapy as a Secondary Treatment for Recurrent Colorectal Cancer with Long-Term Survival].
Yukimoto R; Fukunaga M; Konishi K; Matsuno Y; Nakai S; Takiguchi N; Honda S; Saito A; Takeoka T; Okada K; Ota H; Yokoyama S; Kobayashi K
Gan To Kagaku Ryoho; 2019 Feb; 46(2):369-371. PubMed ID: 30914563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
